ClinicalTrials.Veeva

Menu

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

Mass General Brigham logo

Mass General Brigham

Status and phase

Withdrawn
Phase 4

Conditions

Pulmonary Arterial Hypertension

Treatments

Device: Boston Scientific Intravascular Ultrasound
Device: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01508780
2011P000916

Details and patient eligibility

About

It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular remodeling. The investigators believe that this study will help document the nature of beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular structure and function accompany clinical improvement.

Full description

Subjects will have Optical coherence tomography (OCT) and Intravascular Ultrasound (IVUS) imaging during the right heart catheterization that diagnoses them as having PAH. Subjects will start their bosentan and will be followed by monthly clinic visits for 4 months. At 4 months they will have repeat OCT and IVUS imaging.

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. WHO GROUP 1
  2. AGE 18-75
  3. Baseline 6-min walk distance (6MWD) between 200 and 450 m
  4. Diagnosed with pulmonary artery hypertension during right heart catheterization (Mean Pulmonary Artery Pressure > 25mmHg)

General Exclusion Criteria

  1. Pregnant or nursing
  2. Acute or chronic illness other than those associated with PAH (collagen vascular disease, human immunodeficiency virus, or anorexigen use)
  3. Previously received any investigational medications, prostanoids, or phosphodiesterase inhibitors
  4. eGFR < 60
  5. Angina
  6. Syncope
  7. Failing right ventricle
  8. Hemoptysis

Trial design

0 participants in 1 patient group

Pulmonary Arterial Hypertension, bosentan
Experimental group
Description:
Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
Treatment:
Device: St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)
Device: Boston Scientific Intravascular Ultrasound

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems